Sign Up

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP, providing the potential for access to up to $21 million in capital.

The financing includes:

A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.

A $15 million standby equity purchase agreement (SEPA), which Rein may use at its discretion over 36 months, subject to an effective registration statement.

Rein intends to use the proceeds from these facilities to support its RENEW Phase 2 trial of its lead asset, LTI-03, for the treatment of idiopathic pulmonary fibrosis (IPF), for the research and development of other product candidates, and for working capital and other general corporate purposes.

Key Terms

Pre-paid Advance Facility: Up to $6 million may be drawn over the next twelve months in mutually agreed tranches. Each pre-paid advance will be purchased at a 5% discount, bears interest, and if and when requested by Yorkville, will be repaid in common stock of the company at a discounted price.  

SEPA: Rein has the option, but not the obligation, to sell to Yorkville up to $15 million of common stock over 36 months. Sales under the SEPA require a registration statement to be declared effective by the SEC.

A more detailed description of the agreements will be filed in Rein's Form 8-K with the SEC.

Legal Notice

The shares issuable under the pre-paid advance agreement are being offered by Rein pursuant to a shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission ...